Skip to main content
EJNMMI Research

Table 5 2TCM and SRTM-derived BPND of [18F]FEt-AMC13 per brain region in control and raclopride-treated rats

From: Synthesis and evaluation in rats of homologous series of [18F]-labeled dopamine D2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers

Region of interest

2TCM BPND (V T-based)

SRTM BPND

Control

Raclopride

Control

Raclopride

Striatum

0.56 ± 0.05

0.41 ± 0.05 (−27%)*

0.51 ± 0.02

0.38 ± 0.05 (−26%)**

Hippocampus

0.30 ± 0.07

0.26 ± 0.06 (−13%)

0.26 ± 0.04

0.23 ± 0.05 (−13%)

Thalamus

0.33 ± 0.02

0.30 ± 0.01 (−10%)*

0.28 ± 0.06

0.26 ± 0.02 (−7%)

Hypothalamus

0.22 ± 0.03

0.18 ± 0.06 (−19%)

0.21 ± 0.03

0.16 ± 0.04 (−23%)

Cortex

0.13 ± 0.04

0.10 ± 0.02 (−27%)

0.11 ± 0.03

0.08 ± 0.02 (−24%)

Brainstem

0.22 ± 0.02

0.10 ± 0.02 (−53%)**

0.18 ± 0.04

0.07 ± 0.03 (−60%)**

Olfactory bulbs

0.08 ± 0.13

0.01 ± 0.04 (−88%)

0.10 ± 0.13

0.11 ± 0.05 (+10%)

Pituitary

0.36 ± 0.07

0.13 ± 0.04 (−23%)

0.71 ± 0.32

0.55 ± 0.53 (−22%)

  1. Data are presented as means ± SD, n = 4 for the control group and n = 3 for the raclopride-treated group (except for the SRTM BPND values, where n = 4). Next to the BPND values of the raclopride-treated group, percentage of change relative to the control group is shown
  2. *p < 0.05; **p < 0.01, 2-sided Welch test
Back to article page